Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography
β Scribed by Michael J. Glantz; John M. Hoffman; R. Edward Coleman; Allan H. Friedman; Michael W. Hanson; Peter C. Burger; James E. Herndon PhD II; William J. Meisler; Dr S. Clifford Schold Jr.
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 908 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Second primary tumors are a leading cause of death among patients with head and neck cancer; therefore, early detection of these tumors is necessary. In the current study, the authors aimed to evaluate the diagnostic capacity of 18 F-fluorodeoxyglucose dual-head positron emission t
## Abstract ## BACKGROUND Patients with recurrent oral squamous cell carcinoma (OSCC) have a dismal prognosis and represent a therapeutic challenge. A positron emission tomography (PET) scan with [^18^F]β2βfluorodeoxyglucose ([^18^F]FDG) can improve early cancer detection. The current study evalua
## Abstract We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian c
## Abstract ## BACKGROUND To assess the ability of [^18^F]fluorodeoxyglucose (Fβ18 FDG) positron emission tomography (PET) to predict the viability of residual masses after chemotherapy in patients with metastatic nonseminomatous germ cell tumors (GCT), PET results were compared in a blinded analy